vs

Side-by-side financial comparison of GRAFTECH INTERNATIONAL LTD (EAF) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

GRAFTECH INTERNATIONAL LTD is the larger business by last-quarter revenue ($116.5M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -13.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-39.3M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -7.7%).

GrafTech International Ltd. is a manufacturer of graphite electrodes and petroleum coke, which are essential for the production of electric arc furnace steel and other metals. Headquartered in Brooklyn Heights, Ohio, it has manufacturing facilities in Calais, France;Pamplona, Spain; Monterrey, Mexico; and St. Marys, Pennsylvania.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

EAF vs PBYI — Head-to-Head

Bigger by revenue
EAF
EAF
1.5× larger
EAF
$116.5M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+41.0% gap
PBYI
27.7%
-13.2%
EAF
More free cash flow
PBYI
PBYI
$53.6M more FCF
PBYI
$14.4M
$-39.3M
EAF
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-7.7%
EAF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EAF
EAF
PBYI
PBYI
Revenue
$116.5M
$75.5M
Net Profit
$-65.1M
Gross Margin
-20.9%
69.3%
Operating Margin
-33.6%
22.7%
Net Margin
-55.9%
Revenue YoY
-13.2%
27.7%
Net Profit YoY
-31.6%
EPS (diluted)
$-6.86
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EAF
EAF
PBYI
PBYI
Q4 25
$116.5M
$75.5M
Q3 25
$144.0M
$54.5M
Q2 25
$131.8M
$52.4M
Q1 25
$111.8M
$46.0M
Q4 24
$134.2M
$59.1M
Q3 24
$130.7M
$80.5M
Q2 24
$137.3M
$47.1M
Q1 24
$136.6M
$43.8M
Net Profit
EAF
EAF
PBYI
PBYI
Q4 25
$-65.1M
Q3 25
$-28.5M
$8.8M
Q2 25
$-86.9M
$5.9M
Q1 25
$-39.4M
$3.0M
Q4 24
$-49.5M
Q3 24
$-36.1M
$20.3M
Q2 24
$-14.8M
$-4.5M
Q1 24
$-30.9M
$-4.8M
Gross Margin
EAF
EAF
PBYI
PBYI
Q4 25
-20.9%
69.3%
Q3 25
7.2%
77.7%
Q2 25
0.0%
76.5%
Q1 25
-1.5%
77.1%
Q4 24
-7.8%
76.4%
Q3 24
-9.2%
63.9%
Q2 24
2.9%
77.4%
Q1 24
-1.0%
75.5%
Operating Margin
EAF
EAF
PBYI
PBYI
Q4 25
-33.6%
22.7%
Q3 25
-3.6%
17.6%
Q2 25
-11.0%
12.7%
Q1 25
-16.3%
8.7%
Q4 24
-18.6%
22.6%
Q3 24
-20.1%
27.4%
Q2 24
-2.0%
-4.6%
Q1 24
-15.6%
-5.3%
Net Margin
EAF
EAF
PBYI
PBYI
Q4 25
-55.9%
Q3 25
-19.8%
16.2%
Q2 25
-65.9%
11.2%
Q1 25
-35.2%
6.5%
Q4 24
-36.9%
Q3 24
-27.6%
25.2%
Q2 24
-10.7%
-9.6%
Q1 24
-22.6%
-11.0%
EPS (diluted)
EAF
EAF
PBYI
PBYI
Q4 25
$-6.86
$0.26
Q3 25
$-1.10
$0.17
Q2 25
$-0.34
$0.12
Q1 25
$-0.15
$0.06
Q4 24
$-3.51
$0.40
Q3 24
$-1.40
$0.41
Q2 24
$-0.06
$-0.09
Q1 24
$-0.12
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EAF
EAF
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$1.1B
$22.7M
Stockholders' EquityBook value
$-259.6M
$130.3M
Total Assets
$1.0B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EAF
EAF
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$120.7M
$96.8M
Q1 24
$165.2M
$107.2M
Total Debt
EAF
EAF
PBYI
PBYI
Q4 25
$1.1B
$22.7M
Q3 25
$1.1B
$34.0M
Q2 25
$1.1B
$45.3M
Q1 25
$1.1B
$56.7M
Q4 24
$1.1B
$68.0M
Q3 24
$929.5M
$79.3M
Q2 24
$928.2M
$90.7M
Q1 24
$926.9M
$102.0M
Stockholders' Equity
EAF
EAF
PBYI
PBYI
Q4 25
$-259.6M
$130.3M
Q3 25
$-194.4M
$115.3M
Q2 25
$-168.4M
$104.7M
Q1 25
$-105.3M
$97.1M
Q4 24
$-78.9M
$92.1M
Q3 24
$-9.0M
$71.1M
Q2 24
$16.2M
$48.5M
Q1 24
$37.6M
$51.0M
Total Assets
EAF
EAF
PBYI
PBYI
Q4 25
$1.0B
$216.3M
Q3 25
$1.1B
$202.9M
Q2 25
$1.1B
$194.9M
Q1 25
$1.2B
$196.2M
Q4 24
$1.2B
$213.3M
Q3 24
$1.1B
$220.7M
Q2 24
$1.2B
$205.0M
Q1 24
$1.2B
$214.1M
Debt / Equity
EAF
EAF
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
57.16×
1.87×
Q1 24
24.64×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EAF
EAF
PBYI
PBYI
Operating Cash FlowLast quarter
$-20.9M
$14.4M
Free Cash FlowOCF − Capex
$-39.3M
$14.4M
FCF MarginFCF / Revenue
-33.7%
19.1%
Capex IntensityCapex / Revenue
15.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-120.5M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EAF
EAF
PBYI
PBYI
Q4 25
$-20.9M
$14.4M
Q3 25
$24.7M
$9.7M
Q2 25
$-53.2M
$14.1M
Q1 25
$-32.2M
$3.6M
Q4 24
$-26.4M
$15.6M
Q3 24
$23.7M
$11.0M
Q2 24
$-36.9M
$1.0M
Q1 24
$-530.0K
$11.2M
Free Cash Flow
EAF
EAF
PBYI
PBYI
Q4 25
$-39.3M
$14.4M
Q3 25
$18.4M
$9.7M
Q2 25
$-57.1M
$14.1M
Q1 25
$-42.5M
$3.6M
Q4 24
$-39.2M
$15.6M
Q3 24
$19.7M
$11.0M
Q2 24
$-43.8M
$1.0M
Q1 24
$-11.0M
FCF Margin
EAF
EAF
PBYI
PBYI
Q4 25
-33.7%
19.1%
Q3 25
12.8%
17.7%
Q2 25
-43.3%
26.8%
Q1 25
-38.0%
7.7%
Q4 24
-29.2%
26.4%
Q3 24
15.1%
13.7%
Q2 24
-31.9%
2.1%
Q1 24
-8.1%
Capex Intensity
EAF
EAF
PBYI
PBYI
Q4 25
15.8%
0.0%
Q3 25
4.4%
0.0%
Q2 25
3.0%
0.0%
Q1 25
9.2%
0.1%
Q4 24
9.5%
0.0%
Q3 24
3.1%
0.0%
Q2 24
5.1%
0.0%
Q1 24
7.7%
0.0%
Cash Conversion
EAF
EAF
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EAF
EAF

Graphite Electrodes$107.0M92%
By Products And Other$9.4M8%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons